Skip to main content
SpringerLink
Log in
Book cover

Managing BRCA Mutation Carriers pp 135–150Cite as

Medical Management of Breast Cancer in BRCA Mutation Carriers

  • Chapter
  • First Online:

  • 633 Accesses

Abstract

BRCA mutation-associated breast cancer differs from sporadic breast cancer as studies show that they have higher risk of breast and ovarian cancer and also has differential sensitivity to chemotherapeutic agents. It is an accepted general opinion that breast cancer outcome for BRCA1/2 mutation carriers is at least as good as for non-carriers. On the other hand, we know that BRCA1 and BRCA2 mutation carriers have a lifetime risk of breast cancer in the ranges 47–66% and 40–57%, respectively. Additionally, women with BRCA mutation-associated breast cancer also have an elevated risk of other or secondary malignancies. Therefore, identification of those who might have a mutation is important so that genetic counseling, testing, screening, and prevention strategies can be applied. This article reviews the sensitivity of BRCA-defective breast cancer cell lines to platinum cytotoxic compounds, poly (ADP-ribose) polymerase inhibitors, and endocrine therapy is reviewed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Rev Cancer. 2012;12(1):68–78.

    Article  CAS  Google Scholar 

  2. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 1999;59(15):3547–51.

    CAS  PubMed  Google Scholar 

  3. Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 1999;285(5428):747–50.

    Article  CAS  PubMed  Google Scholar 

  4. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995;10(8):1673–5.

    CAS  PubMed  Google Scholar 

  5. Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BA, et al. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer. 1995;13(3):203–10.

    Article  CAS  PubMed  Google Scholar 

  6. Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, et al. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene. 1999;18(32):4643–6.

    Article  CAS  PubMed  Google Scholar 

  7. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564–9.

    Article  CAS  PubMed  Google Scholar 

  8. Tapia T, Smalley SV, Kohen P, Munoz A, Solis LM, Corvalan A, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics. 2008;3(3):157–63.

    Article  PubMed  Google Scholar 

  9. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE. Methylation not a frequent “second hit” in tumors with germline BRCA mutations. Fam Cancer. 2009;8(4):339–46.

    Article  CAS  PubMed  Google Scholar 

  10. Collins N, Wooster R, Stratton MR. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer. 1997;76(9):1150–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surgical Oncol. 2014.

    Google Scholar 

  12. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143–53.

    Article  CAS  PubMed  Google Scholar 

  13. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005;18(10):1305–20.

    Article  CAS  PubMed  Google Scholar 

  14. Gerdes AM, Cruger DG, Thomassen M, Kruse TA. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin Genet. 2006;69(2):171–8.

    Article  PubMed  Google Scholar 

  15. Melchor L, Benitez J. The complex genetic landscape of familial breast cancer. Human Genet. 2013;132(8):845–63.

    Article  CAS  Google Scholar 

  16. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia. 2004;9(3):221–36.

    Article  PubMed  Google Scholar 

  17. Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, Salazar R, et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat. 2003;22(4):301–12.

    Article  CAS  PubMed  Google Scholar 

  18. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121(2):269–75.

    Article  CAS  PubMed  Google Scholar 

  19. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134–47.

    Article  CAS  PubMed  Google Scholar 

  20. King MC, Marks JH, Mandell JB. New York breast cancer study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6.

    Article  CAS  PubMed  Google Scholar 

  21. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Human Genet. 2003;72(5):1117–30.

    Article  CAS  Google Scholar 

  22. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Nat Cancer Inst. 2009;101(2):80–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am JHuman Genet. 1995;56(1):265–71.

    Google Scholar 

  25. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222–6.

    Article  CAS  PubMed  Google Scholar 

  26. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282–8.

    Article  PubMed  Google Scholar 

  27. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77(4):697–709.

    Article  CAS  PubMed  Google Scholar 

  28. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res. 1998;58(8):1588–92.

    CAS  PubMed  Google Scholar 

  29. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000;6(3):782–9.

    CAS  PubMed  Google Scholar 

  30. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.

    Article  CAS  PubMed  Google Scholar 

  31. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, et al. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res. 2009;2(2):122–7.

    Article  CAS  Google Scholar 

  32. Kennedy RDQJ, Johnston PH, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet. 2002;360:1007–14.

    Article  CAS  PubMed  Google Scholar 

  33. Verhoog LCBC, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999;17:3396–402.

    Article  CAS  PubMed  Google Scholar 

  34. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(2):115–23.

    Article  CAS  PubMed  Google Scholar 

  35. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, B. Eur J Cancer. 2007;43:867–76.

    Google Scholar 

  36. Kriege MSC, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, et al. Distant disease-free interval, site of first relapse and post-relapse survival in B. Breast Cancer Res Treat. 2008;111:303–11.

    Article  PubMed  Google Scholar 

  37. Bonadona V D-MS, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, Bremond A, et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat. 2007;101(2):233–45.

    Google Scholar 

  38. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 119(1):13–24.

    Google Scholar 

  39. Robson MLD, Federici M, Satagopan J, Bogolminy F, Heerdt A, Borgen P, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999;91:2112–7.

    Article  CAS  PubMed  Google Scholar 

  40. Chappuis POKL, Bégin LR, Wong N, Brunet JS, Narod SA, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000;18:4045–52.

    Article  CAS  PubMed  Google Scholar 

  41. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, et al. Familial invasive breast cancer: worse outcome related to BRCA1 mutations. J Clin Oncol. 2000;18:4053–9.

    Article  CAS  PubMed  Google Scholar 

  42. Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, et al. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer. 2007;121(5):1017–20.

    Article  CAS  PubMed  Google Scholar 

  43. Lee EH, Park SK, Park B, Kim SW, Lee MH, Ahn SH, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 122(1):11–25.

    Google Scholar 

  44. Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. 117(14):3093–100.

    Google Scholar 

  45. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130(1):145–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status. Cancer. 2016;122(8):1178–84.

    Article  CAS  PubMed  Google Scholar 

  47. Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1/2 on Ovarian and breast cancer survival-response. Clin Cancer Res. 2015;21(16):3807.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–63.

    Article  CAS  PubMed  Google Scholar 

  49. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375–9.

    Article  CAS  PubMed  Google Scholar 

  50. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29(28):3739–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Wen J, Li R, Lu Y, Shupnik MA. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene. 2009;28(4):575–86.

    Article  PubMed  Google Scholar 

  53. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.

    Article  CAS  PubMed  Google Scholar 

  54. Iglehart JD, Silver DP. Synthetic lethality—a new direction in cancer-drug development. N Engl J Med. 2009;361(2):189–91.

    Article  CAS  PubMed  Google Scholar 

  55. Carey LA, Sharpless NE. PARP and cancer—if it’s broke, don’t fix it. N Engl J Med. 2011;364(3):277–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Nat Cancer Inst. 2004;96(22):1659–68.

    Article  CAS  PubMed  Google Scholar 

  57. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88(8):1285–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006;5(9):1001–7.

    Article  CAS  PubMed  Google Scholar 

  59. Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147(2):401–5.

    Article  CAS  PubMed  Google Scholar 

  60. Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2012;14(4):R110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham J, et al. The TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast cancer. Tutt A E. SABC. 2014;S3–01.

    Google Scholar 

  62. Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, Boughey JC, et al. Neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy. San Antonio Breast Cancer Symp. 2015.

    Google Scholar 

  63. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. 118(4):899–907.

    Google Scholar 

  64. von Minckwitz G, Hahnen E, Fasching PA, et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. 2014 ASCO Annual Meeting, J Clin Oncol. 2014;32(suppl; abstr 1005):5s.

    Google Scholar 

  65. Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, Connor C, Gomez HL, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts. Clin Cancer Res. 2017;23(3):649–57.

    Article  CAS  PubMed  Google Scholar 

  66. McAndrew NP, Maxwell KN, Stopfer J, et al. Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer. J Clin Oncol. 2015;33(suppl; abstr 541).

    Google Scholar 

  67. Byrski T, Blum JL, Goncalves A, Campone M, et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol. 2014;25(6):1152–8.

    Article  PubMed  Google Scholar 

  68. Tedesco KL. Final results of a phase II trial of trabectedin (T) in triple-negative H-p, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). ASCO Annu Meet. 2011, suppl abstract 1125.

    Google Scholar 

  69. Delaloge S, Wolp-Diniz R, Byrski T, et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol. 2014;25(6):1152–8.

    Article  CAS  PubMed  Google Scholar 

  70. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays. 2004;26(8):882–93.

    Article  CAS  PubMed  Google Scholar 

  71. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry. 2000;39(25):7559–69.

    Article  CAS  PubMed  Google Scholar 

  72. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.

    Article  CAS  PubMed  Google Scholar 

  73. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–90.

    Article  CAS  PubMed  Google Scholar 

  74. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

    Article  CAS  PubMed  Google Scholar 

  75. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.

    Article  CAS  PubMed  Google Scholar 

  76. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44.

    Article  CAS  PubMed  Google Scholar 

  77. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–51.

    Article  CAS  PubMed  Google Scholar 

  78. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50.

    Article  CAS  PubMed  Google Scholar 

  79. Puhalla S, Beumer JH, Pahuja S, et al. Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol. 2014;32(suppl; abstr 2570):5s.

    Google Scholar 

  80. Somlo G, Frankel PH, Luu TH, et al.BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96. 2014 ASCO Annual Meeting. J Clin Oncol. 2014;32(suppl; abstr 1021):5s.

    Google Scholar 

  81. Drew Y, Ledermann JA, Jones A, Hall G, Jayson GC, Highley M, et al. Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA-1 and -2 mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. J Clin Oncol. 2011;29:3104.

    Article  Google Scholar 

  82. Sk Sandhu, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92.

    Article  Google Scholar 

  83. De Bono JS, Mina LA, Gonzalez M, et al.First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. 2013ASCO Annual Meeting JCO, J Clin Oncol. 2013;31(suppl; abstr 2580).

    Google Scholar 

  84. Turner NC, Balmaña J, Fasching PA, et al. A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO). 2015 ASCO Annual Meeting, J Clin Oncol. 2015;33(suppl; abstr TPS1108).

    Google Scholar 

  85. Litton JK, Blum JL, Im Y-H, et al. A phase 3 o-l, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). 2015 ASCO Annual Meeting, J Clin Oncol. 2015;33(suppl; abstr TPS1107).

    Google Scholar 

  86. Piha-Paul SA, Goldstein JB, Hess KR, et al. Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2 mdiPoPl, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer). 2015 ASCO Annual Meeting, J Clin Oncol. 2015;33(suppl; abstr TPS2617).

    Google Scholar 

  87. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281–4.

    Article  CAS  PubMed  Google Scholar 

  88. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group. Lancet. 2000;356(9245):1876–81.

    Article  CAS  PubMed  Google Scholar 

  89. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24(16):2437–43.

    Article  PubMed  Google Scholar 

  90. Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328–35.

    Article  CAS  PubMed  Google Scholar 

  92. Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat. 2010;123(2):491–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer. 2005;103(1):44–51.

    Article  PubMed  Google Scholar 

  94. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6(1):R8–17.

    Article  CAS  PubMed  Google Scholar 

  95. Phillips K-A, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31:3091–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Wesolowski R SA, Tao J, Moore HC, editor. Differential outcomes in patients treated with endocrine therapy for early or locally advanced breast cancer based on BRCA mutation status. 2009 ASCO Annual Meeting. J Clin Oncol. 2009;27(suppl; abstr e22065).

    Google Scholar 

  97. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/CAf,%20american-cancer-society-guidelines-for-theearly-,%20detection-of-cancer. Accessed Dec 6.

  99. Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the society of breast imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol JACR. 2010;7(1):18–27.

    Article  PubMed  Google Scholar 

  100. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011;117(17):3900–7.

    Article  PubMed  Google Scholar 

  101. NCCN GFH-RABaO, Available CPGiOv, http://www.nccn.org/professionals/physician_gls/pdf/f,%20genetics_screening.pdf. Accessed Dec 9.

  102. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am. 2000;84(3):707–18.

    Article  CAS  PubMed  Google Scholar 

  103. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2(7):606–21.

    Article  PubMed  Google Scholar 

  104. Cancer: UPSTFSfC, AHRQ UPSTFRS, http://www.ahrq.gov/P-E-Af,%20clinic/uspstf08/colocancer/colors.htm. Accessed Dec 2.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Memorial Cancer Center, Piyalepasa Bulvari, Sisli, 34340, Istanbul, Turkey

    Soley Bayraktar

  2. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX, 77030-4009, USA

    Banu K. Arun

Authors
  1. Soley Bayraktar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Banu K. Arun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Banu K. Arun .

Editor information

Editors and Affiliations

  1. Yale Comprehensive Cancer Center, Yale University School of Medicine Yale Comprehensive Cancer Center, New Haven, Connecticut, USA

    Anees B. Chagpar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Bayraktar, S., Arun, B.K. (2017). Medical Management of Breast Cancer in BRCA Mutation Carriers. In: B. Chagpar, A. (eds) Managing BRCA Mutation Carriers . Springer, Cham. https://doi.org/10.1007/978-3-319-59198-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59198-8_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59197-1

  • Online ISBN: 978-3-319-59198-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation